Objectives: To evaluate the safety and clinical outcomes of patients who received carbapenem de-escalation as guided by an antimicrobial stewardship programme (ASP) in a setting where ESBL-producing Enterobacteriaceae are endemic.
Introduction
Empirical broad-spectrum antimicrobials are advocated as part of the treatment strategy for serious bacterial infections as inadequate initial therapy or a delay in giving an active antimicrobial has been associated with increased mortality, morbidity and duration of hospitalization. 1, 2 However, the excessive use of broad-spectrum antimicrobials selects for resistant organisms. 3 Hence, a timely de-escalation of broad-spectrum therapy, while taking into account microbiological data and the patient's clinical response, constitutes an important part of the treatment strategy. 2, 4 This is integral to an antimicrobial stewardship programme (ASP) whose mission is to promote the judicious use of antimicrobials, optimize patient outcomes and reduce the risk and cost of the development of resistance. 5 Carbapenems are appropriate empirical therapy in patients with moderate to severe infections and risk factors for infection with MDR Gram-negative organisms. These risk factors include prior colonization/infection with ESBL or AmpC b-lactamase producers and patients who are at risk of acquiring such organisms, e.g. in endemic settings. Carbapenems may also be appropriate second-line therapy in cases where prior therapy with other antimicrobial classes with Gram-negative activity, such as cephalosporins and fluoroquinolones, have failed. 6 However, there is often a reluctance to de-escalate these broad-spectrum antimicrobials once they have been initiated. These concerns may be legitimate given the paucity of data in settings where Gram-negative resistance is endemic. 7 We conducted a study to evaluate the safety and clinical outcomes of carbapenem de-escalation as guided by our ASP in an ESBL-endemic setting.
Methods

Study setting
Tan Tock Seng Hospital (TTSH) is a 1500 bed acute care academic hospital and ASP was established in 2009. Due to our high endemicity of MDR Gram-negative bacteria, notably the fact that 29.0% of all Escherichia coli and 40.0% of Klebsiella pneumoniae isolates cultured in our clinical microbiology laboratory are ESBL producers, carbapenems are often empirically prescribed for the treatment of healthcare-associated and hospital-acquired infections. Hence one of the key strategies of the ASP is to review carbapenem use and recommend de-escalation where appropriate. De-escalation includes narrowing the spectrum of antibacterial coverage based on the clinical response, culture results and susceptibility of the pathogens identified, and stopping antimicrobials when the treatment course is completed or when no infection is identified. 4, 6 The TTSH ASP team comprises four infectious disease (ID) physicians on rotation (making up 0.5 full-time equivalents daily) and three ASP pharmacists. Cases are reviewed every working weekday (8am to 5pm) from the day of carbapenem initiation. The carbapenem orders are reviewed on Days 1 and 2 by the ward pharmacists for appropriate indication(s) and dosage based on evidence-based, institutionally approved antimicrobial guidelines. The ward pharmacists and ASP team review the patients from Day 3 of carbapenem use for a de-escalation opportunity based on clearly defined criteria ( Figure 1 ). The choice of antimicrobials for de-escalation in empirical therapy is governed by the hospital antimicrobial guidelines, while that for definitive therapy is based on culture and susceptibility results. Following the prospective reviews, feedback including recommendations such as de-escalation, escalation to broader antimicrobial coverage, switching to oral antimicrobials, dose optimization and additional diagnostic tests are made to the primary care team where appropriate. All recommendations, including reasons for de-escalation, are communicated to the primary care team through documentation in the patient's chart and frequently include telephone or in-person discussions. Cases where the primary care team does not accept the ward pharmacist's recommendations or the case is complicated are referred to the ASP team.
The TTSH microbiology laboratory is accredited by the College of American Pathologists and follows the CLSI standards for microbial culture and antimicrobial susceptibility testing (AST). The CLSI combination disc method is used for the phenotypic confirmation of ESBL production for E. coli, Klebsiella spp. and Proteus mirabilis. In our study, Enterobacter spp., Serratia spp., Citrobacter freundii, Proteus vulgaris, Providencia spp. and Morganella morganii were considered to be inherent AmpC b-lactamase producers. The identification of pathogens from clinical specimens is usually reported within 2 -3 days and the AST results within 3-4 days.
Patients, data collection and outcome definitions
This was a retrospective study of hospitalized patients taking imipenem and meropenem who were reviewed by ward pharmacists or the ASP team from September 2011 to December 2012, for whom a recommendation for de-escalation was made. Patients who received more than one course of carbapenems within this period were only included once in the study. Carbapenems in this study only refer to the full-spectrum Lew et al.
carbapenems, specifically imipenem and meropenem (doripenem is not available in our hospital); 6 ertapenem was excluded as it is a narrower spectrum carbapenem recommended for the de-escalation from imipenem or meropenem, where appropriate, in this study.
Data were abstracted from electronic medical records and inpatient medication records. The abstracted data included age, gender, location of care at the time of the ASP recommendation (general ward or ICU), whether therapy was empirical or culture directed, the site(s) of infections and the bacteria isolated. APACHE II and age-adjusted Charlson comorbidity scores were used to compare the disease severity and comorbidities between the groups. 8, 9 Conditions meeting the criteria for de-escalation were also recorded.
The primary outcome for this study was the proportion of patients who achieved clinical success. Clinical success was considered to have been achieved when the patient fulfilled all of the following criteria at 7 days after the ASP recommendation for de-escalation: (i) the patient was alive; (ii) there were no positive microbiological results; (iii) the patient did not require a readministration of carbapenem or the addition of other antimicrobials; and (iv) the patient still met the criteria for de-escalation ( Figure 1 ).
Secondary outcomes evaluated were the duration of carbapenem use, the total duration of antimicrobial therapy, the length of hospitalization, the survival at hospital discharge, the 30 day mortality from the start of treatment with the carbapenem and readmission to hospital due to infection within 30 days.
In addition, the study examined the incidence of documented adverse drug reactions. Information on adverse drug reactions secondary to antimicrobials was abstracted from the patients' medical records. Also, as markers of 'collateral damage' to normal bacterial flora, we collected data on the acquisition of carbapenem-resistant Gram-negative bacteria, Clostridium difficile-associated diarrhoea (CDAD) and the isolation of Candida sp. (from sterile sources) within 30 days from the start of carbapenem use.
The outcomes were compared between the groups that de-escalated and did not de-escalate carbapenem therapy as guided by the ASP.
Statistical analysis
The ratio of acceptance to rejection of the ASP recommendation in our institution is 2:1; hence the sample size required for this study to have an 80% power to detect a 10% difference in the primary outcome using a two-sided test with an a level of 0.05 was calculated to be 196 in the de-escalated group and 98 in the not de-escalated group. Accordingly, 300 patients in the eligible cohort were randomly selected for study inclusion. The x 2 test or Fisher's exact test was used to analyse the categorical data, while the Student's t-test or Wilcoxon rank sum test was used to analyse the continuous data, where appropriate. P values ≤0.05 were considered statistically significant. Statistical analysis was performed using IBM SPSS Statistics 20.0.
Study approval
This study was approved by our Institutional Review Board.
Results
A total of 2433 courses of meropenem and imipenem were reviewed between September 2011 and December 2012, with 428 recommendations for de-escalation being made for 400 unique patients. Three-hundred patients were randomly selected for inclusion in the study, of whom 204 (68.0%) received a de-escalation of carbapenem as guided by the ASP, while 96 (32.0%) did not.
The patient demographics including gender, age and location of care at the time of the ASP recommendation were similar between groups, as were the type of therapy (empirical or culture directed) and the severity of illness according to APACHE II and the Charlson comorbidity index ( Table 1) . The most common site of infection recommended for de-escalation was the urinary tract (112/300, 37.3% of recommendations). There was a higher rate of de-escalation for hepatobiliary infections and a lower rate for skin and soft tissue infections. There were higher proportions of ESBL-producing Enterobacteriaceae and AmpC b-lactamaseproducing Enterobacteriaceae in the not de-escalated group compared with the de-escalated group, although this was not statistically significant.
The most common criterion for de-escalation in both groups was the availability of narrower spectrum antibiotics when susceptibility results were available. A discontinuation of antibiotics was recommended for 113 patients (37.7% of all recommendations) and ertapenem was the most common antibiotic recommended as de-escalation therapy from meropenem or imipenem (44/300, 14.7%) ( Table 1) .
There were 183/204 (89.7%) and 85/96 (88.5%) clinical successes in the de-escalated and not de-escalated groups, respectively (P ¼0.84). The secondary outcomes of survival at discharge, 30 day mortality from the start of carbapenem therapy and 30 day readmission due to infection were similar between the groups (Table 2) . De-escalation did not affect the duration of hospitalization (as counted from the initiation of carbapenem therapy) or the total duration of antimicrobial therapy. However, the group that de-escalated had a significantly shorter duration of carbapenem use [median (IQR), 6 (4 -8) versus 8 (7 -11) days, P,0.001].
The de-escalated group had fewer patients with adverse drug reactions [11/204 (5.4%) versus 12/96 (12.5%), P ¼ 0.037], driven by a significantly lower rate of antibiotic-associated diarrhoea [9/204 (4.4%) versus 12/96 (12.5%), P ¼ 0.015]. The incidence of rash and neurotoxicity was low in both groups (Table 2) .
At 30 days, a significantly lower incidence of carbapenemresistant Acinetobacter baumannii was isolated from clinical cultures in the de-escalated group [4/204 (2.0%) versus 7/96 (7.3%), P ¼ 0.042], while the acquisition of other carbapenemresistant Gram-negative bacteria was low and comparable in the two groups [6/204 (2.9%) versus 1/96 (1.0%), P ¼ 0.44]. There was a lower incidence of CDAD in the group that deescalated treatment [2/204 (1.0%) versus 4/96 (4.2%), P¼0.081] ( Table 2) .
Discussion
This study demonstrated that the ASP-guided de-escalation of carbapenems did not compromise clinical outcomes and led to a shorter duration of carbapenem use. De-escalation was also associated with a significantly lower incidence of carbapenemresistant A. baumannii acquisition and antibiotic-associated diarrhoea. There was also trend towards a lower incidence of CDAD.
Various studies have evaluated the outcomes of antimicrobial de-escalation and these were predominantly carried out in the intensive care setting in patients with severe sepsis or septic shock. 10, 11 Garnacho-Montero et al. 12 studied 628 patients with severe sepsis or septic shock in an ICU, of whom 219 patients ASP-guided carbapenem de-escalation received a de-escalation of empirical broad-spectrum antibiotics (carbapenem constituted 22%). De-escalation was found to be a protective factor against mortality even after adjusting for illness severity (OR 0.54, 95% CI 0.33 -0.89). The protective effect of de-escalation has also been observed in other studies of ICU patients with hospital-acquired pneumonia. 11, 13 Of note, only 6% of our cohort was in the ICU at the time of the ASP-guided de-escalation. This is because a separate multidisciplinary ICU ID team provides guidance for antibiotic therapy in the critical care units in our institution.
In a retrospective review, Shime et al. 14 examined the safety and effectiveness of antimicrobial de-escalation in treating bacteraemia due to antibiotic-susceptible pathogens. They reported that the de-escalated versus escalated or unchanged groups trended towards a lower treatment failure (4% versus 10%) and mortality (1% versus 5%). In our study, almost half of the recommendations for de-escalation were made after the AST results were known. Their results, and ours, reinforce the safety and effectiveness of de-escalation in culture-directed therapy.
Few studies have evaluated the impact of carbapenem de-escalation. De Waele et al. 15 evaluated meropenem de-escalation in a surgical ICU in Belgium, where 30% of the Enterobacteriaceae that were isolated were ESBL producers. They included 72 cases of empirical meropenem use, 42% of which were de-escalated. Despite the similar APACHE score, there was a trend towards a lower mortality rate in the group ASP-guided carbapenem de-escalation 1223 JAC that de-escalated (7% versus 21%, P ¼ 0.12), similar to the findings from our study.
Another recent study in Thailand by Apisarnthanarak et al.
16
evaluated 253 patients who had been prescribed meropenem, imipenem or doripenem over a 2 year period. ESBL-producing Enterobacteriaceae and MDR Pseudomonas and Acinetobacter made up 41.5% of the pathogens isolated. Similar to our study, they found no difference in mortality in the group that de-escalated compared with those who did not de-escalate (13.2% versus 16.2%, P ¼0.35) and a shorter duration of carbapenem exposure in the de-escalated group (5 versus 12 days, P,0.001). In their study, carbapenem de-escalation was based on the discretion of the individual physician, although ID consultation was associated with de-escalation, while all the cases in our study were evaluated by and received guidance for de-escalation from the ASP team. Clinical success was achieved in 183/204 (89.7%) patients with carbapenem de-escalated in our study. We believe that this demonstrates the importance of systematic patient evaluation and selection for de-escalation, which is the strength of our ASP-guided carbapenem de-escalation. A systemic review performed by Davey et al. 17 examined the effectiveness of interventions to decrease antibiotic use on antimicrobial usage and their impact on clinical outcome, including their impact on the incidence of CDAD. In nine studies that reported clinical outcomes, two reported deteriorations (in length of hospital stay and crude 30 day readmission, respectively) and three reported improvements. Although none of the studies specifically examined carbapenem de-escalation and hence cannot be directly compared with ours, this systemic review demonstrated that different and even conflicting results from de-escalation might be expected due to the heterogeneity of the interventions, institutional practices, institutional guidelines and patient populations. This again points to the argument that a careful selection of appropriate patients for de-escalation as guided by ASP will be important in ensuring positive clinical outcomes.
As far as we know, none of the previous studies on carbapenem de-escalation reported their impact on the acquisition of MDR organisms, although various studies have demonstrated the association between the restriction of broad-spectrum antimicrobials and a lower incidence of CDAD and infection with MDR Gram-negative organisms. 18 -22 A recent study by our group showed that carbapenem and piperacillin/tazobactam use was independently associated with XDR A. baumannii bacteraemia. 23 In this study, we observed a significantly lower incidence of carbapenem-resistant A. baumannii acquisition in the group that underwent de-escalation and there was a trend towards a lower incidence of CDAD.
This study has some limitations. First, the retrospective design limited our ability to study barriers to the de-escalation of broadspectrum antimicrobials. The barriers identified in previous studies include a history of antibiotic therapy, a history of infection/ colonization by resistant organisms and the clinician's perception that the patient had improved on escalation to broad-spectrum antimicrobials. This may have led to a physician reluctance to de-escalate even when new microbiological data were available. 24, 25 Due to the retrospective design, we were also unable to ascertain the reasons for the higher incidence of patients with a history of myocardial infarction in the de-escalated group, and the incidence of adverse drug reactions was heavily dependent on physician's documentation. We did not find any of the adverse reactions documented to be due to noncarbapenem antibiotics. This is likely to be because only a small number of patients (55/300, 18.0%) required further noncarbapenem antibiotics for more than 3 days in the hospital after carbapenem had been discontinued. Another 30 patients continued non-carbapenem antibiotics on discharge from hospital and the documentation of adverse reactions (if indeed they occurred) might have been limited; nonetheless, these patients were documented to have completed the specified course of antibiotic therapy.
Second, the results obtained from this study may not be generalizable since local practices and guidelines may differ. However, our study shows that even in a setting where ESBLproducing Gram-negative organisms are endemic, ASP recommendations to de-escalate or discontinue carbapenems were safe and did not jeopardize clinical outcomes in patients who fulfilled our de-escalation criteria, shown in Figure 1 . This was coupled with effective communication and documentation that was made available to the primary medical team.
In conclusion, data from this study suggest that carbapenem de-escalation as guided by an ASP led to comparable clinical success, fewer adverse effects and a lower incidence of the development of resistance. The approach is safe and practicable, even in an ESBL-endemic setting, and should be a key component of an ASP.
